Resolve Biosciences Welcomes John Stark as New CEO to Lead the Company Forward

Resolve Biosciences, a leader in Molecular Cartography™ technology, has announced the appointment of John Stark as its new Chief Executive Officer. With this change, Jason Gammack, who has been at the helm of the company since its inception, will be stepping down. John Stark brings with him a wealth of experience and a deep understanding of the industry, and the company looks forward to leveraging his expertise to take Resolve Biosciences to the next level.

Mr. Stark is a life sciences industry veteran, with over 20 years of experience in commercializing early-stage technologies, scaling organizations and leveraging capital markets. Most recently, he served as Chief Executive Officer of Quantum-Si (NASDAQ: QSI), a cutting-edge single-molecule protein sequencing platform company. He also led Celsee, a single-cell genomics platform company, before it was acquired by Bio-Rad (NYSE: BIO) in 2020. Throughout his career, Mr. Stark has held senior leadership positions at some of the most innovative companies, such as Life Technologies (acquired by Thermo Fisher Scientific, NYSE:TMO), Pacific Biosciences (NASDAQ: PACB), and Affymetrix (acquired by Thermo Fisher Scientific).

The Board of Resolve Biosciences is thrilled to welcome John as the leader of their next chapter of growth and success. His impressive record of achievement, operational excellence, and team-building abilities make him the perfect candidate to drive innovation and realize the tremendous potential of spatial biology in science and medicine. With his experience in delivering high-growth results for a variety of industry-defining platforms, the Board is confident that John will be a great addition to the team and help them shape the future of their organization.

Mr. Schatz expressed his gratitude for Jason Gammack’s invaluable contributions and leadership as the former CEO of the organization, praising him for his efforts in successfully navigating the company through the COVID-19 pandemic and launching the commercial platform and service offering.

I am thrilled to join Resolve Biosciences as its next Chief Executive Officer! I am excited to lead this growing company with a ground-breaking technology and an exceptional team. With our Molecular Cartography technology, we will help our global partners and customers gain a better understanding of the molecular causes of disease and associated immune responses. I am committed to delivering superior products that will enable them to reach the full potential of this technology.

About Resolve Biosciences

Resolve Biosciences is revolutionizing the field of spatial biology with their cutting-edge Molecular Cartography™ technology. This proprietary, highly multiplexed, single-molecule detection technology offers unparalleled sensitivity and specificity, granting scientists the ability to detect individual transcripts and rare signals in order to gain new insights. All of this is done while preserving the sample tissue in a fully automated workflow. With applications in oncology, neuroscience, infectious disease, and agriculture, this technology is leading the way in advancing the understanding of complex biological questions. Resolve Biosciences is based in Monheim am Rhein, Germany, and also has a North American facility in San Jose, California.

Leave a Comment